IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03664-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Justin Yu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. Hauptthemen laut MEDLINE: Interleukin-7, Head and Neck Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDCD NIH HHS, NIH HHS.
Abstract (Originalsprache)
Clinically approved head and neck squamous cell carcinoma (HNSCC) immunotherapies manipulate the immune checkpoint blockade (ICB) axis but have had limited success outside of recurrent/metastatic disease. Interleukin-7 (IL7) has been shown to be essential for effector T-cell survival, activation, and proliferation. Here, we show that IL7 in combination with radiotherapy (RT) is effective in activating CD8 + T-cells for reducing tumor growth. Our studies were conducted using both human papillomavirus related and unrelated orthotopic HNSCC murine models. Immune populations from the tumor, draining lymph nodes, and blood were compared between treatment groups and controls using flow cytometry, proteomics, immunofluorescence staining, and RNA sequencing. Treatment with RT and IL7 (RT + IL7) resulted in significant tumor growth reduction, high CD8 T-cell tumor infiltration, and increased proliferation of T-cell progenitors in the bone marrow. IL7 also expanded a memory-like subpopulation of CD8 T-cells. These results indicate that IL7 in combination with RT can serve as an effective immunotherapy strategy outside of the conventional ICB axis to drive the antitumor activity of CD8 T-cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology - Head and Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
- Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
- Radiation Biology Research Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.
- Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. sana.karam@cuanschutz.edu.
Förderung
- NCI NIH HHS
- NIDCD NIH HHS
- NIH HHS
- National Institutes of Health
- NIDCR/NCI
Zitieren
APA
Yu, J., Gadwa, J., Ross, R. B., Knitz, M., Darragh, L. B., Abdelazeem, K. N. M., Beynor, J., Neupert, B., Nguyen, A., Nguyen, D., Olimpo, N., Corbo, S., Van Court, B., D'Alessandro, A., Saviola, A., & Karam, S. D. (2024). IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03664-y
Vancouver
Yu J, Gadwa J, Ross RB, Knitz M, Darragh LB, Abdelazeem KNM, et al. IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03664-y
BibTeX
@article{Yu2024,
author = {Yu, Justin and Gadwa, Jacob and Ross, Richard B and Knitz, Michael and Darragh, Laurel B and Abdelazeem, Khalid N M and Beynor, Jessica and Neupert, Brooke and Nguyen, Alexander and Nguyen, Diemmy and Olimpo, Nicholas and Corbo, Sophia and Van Court, Benjamin and D'Alessandro, Angelo and Saviola, Anthony and Karam, Sana D},
title = {IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03664-y}
}
EUVIMED